"
Team:Paris Bettencourt/Results
From 2013.igem.org
(Difference between revisions)
| Line 35: | Line 35: | ||
</div> | </div> | ||
</div> | </div> | ||
| + | <div class="overbox"> | ||
| + | <div class="bkgr"> | ||
| + | <h2>Background</h2> | ||
| + | <p>SirA is an essential gene in latent tuberculosis infections</p> | ||
| + | </div> | ||
| + | <div class="results"> | ||
| + | <h2>Results</h2> | ||
| + | <ul> | ||
| + | <li>Produced an E. coli strain which relies upon mycobacterial sirA, fprA and fdxA genes to survive in M9 minimal media</li> | ||
| + | <li>Demonstrated that E. coli can survive with mycobacterial sulfite reduction pathway with Flux Balance Analysis</li> | ||
| + | <li>Located drug target sites on sirA as well as identified high structural similarity between cysI and sirA through structural anaylsis</li> | ||
| + | </ul> | ||
| + | <p></p> | ||
| + | </div> | ||
| + | <div class="biocriks"> | ||
| + | <h2>BioBricks</h2> | ||
| + | <ol> | ||
| + | <li><a href="http://parts.igem.org/Part:BBa_K1137000">BBa_K1137000 (SirA)</a></li> | ||
| + | <li><a href="http://parts.igem.org/Part:BBa_K1137001">BBa_K1137001 (FprA)</a></li> | ||
| + | <li><a href="http://parts.igem.org/Part:BBa_K1137002">BBa_K1137002 (FdxA)</a></li> | ||
| + | </ul> | ||
| + | </div> | ||
| + | <div style="clear: both;"></div> | ||
| + | <div class="aims"> | ||
| + | <h2>Aims</h2> | ||
| + | <p>To perform an drug screen targeted at the sirA gene from mycobacteria</p> | ||
| + | </div> | ||
| + | <a href="#Introduction"> | ||
| + | <div class="hlink"> | ||
| + | <h2>Skip to Introduction</h2> | ||
| + | </div> | ||
| + | </a> | ||
| + | <a href="#Model"> | ||
| + | <div class="hlink"> | ||
| + | <h2>Skip to Modeling</h2> | ||
| + | </div> | ||
| + | </a> | ||
| + | <a href="#Design"> | ||
| + | <div class="hlink"> | ||
| + | <h2>Skip to Design</h2> | ||
| + | </div> | ||
| + | </a> | ||
| + | <a href="#Results"> | ||
| + | <div class="hlink" style="margin-right:0px"> | ||
| + | <h2>Skip to Results</h2> | ||
| + | </div> | ||
| + | </a> | ||
| + | <div style="clear: both;"></div> | ||
| + | </div> | ||
</html> | </html> | ||
<!-- ########## Don't edit below ########## --> | <!-- ########## Don't edit below ########## --> | ||
{{:Team:Paris_Bettencourt/footer}} | {{:Team:Paris_Bettencourt/footer}} | ||
Revision as of 23:40, 4 October 2013
Background
CRISPR/Cas systems generate site-specific double strand breaks and have recently be used for genome editing.
Results
- Successfully cloned gRNA anti-KAN, crRNA anti-KAN, tracrRNA-Cas9 and pRecA-LacZ into Biobrick backbones and therefore generated four new BioBricks.
- Testing the new assembly standard for our cloning.
BioBricks
Aims
Building a genotype sensor based on CRISPR/Cas that reports existance of an antibiotic resistance gene.
Background
SirA is an essential gene in latent tuberculosis infections
Results
- Produced an E. coli strain which relies upon mycobacterial sirA, fprA and fdxA genes to survive in M9 minimal media
- Demonstrated that E. coli can survive with mycobacterial sulfite reduction pathway with Flux Balance Analysis
- Located drug target sites on sirA as well as identified high structural similarity between cysI and sirA through structural anaylsis
Aims
To perform an drug screen targeted at the sirA gene from mycobacteria
Skip to Introduction
Skip to Modeling
Skip to Design
Skip to Results
Centre for Research and Interdisciplinarity (CRI)
Faculty of Medicine Cochin Port-Royal, South wing, 2nd floor
Paris Descartes University
24, rue du Faubourg Saint Jacques
75014 Paris, France
+33 1 44 41 25 22/25
team2013@igem-paris.org
+33 1 44 41 25 22/25
team2013@igem-paris.org 
